TABRECTA (capmatinib) tablets, for oral use.

Name: TABRECTA (capmatinib) tablets, for oral use. - South Delhi Pharma
Brand: simple

This specialty medication is manufactured abroad and is not registered or commercially marketed for retail sale in India. Access in India may require specific regulatory approvals or personal import permits as prescribed by relevant authorities. Under Named Patient Supply, SDP can serve you. To know the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

TABRECTA is a prescription medicine for lung cancer (non-small cell lung cancer-NSCLC) treatment.
INDICATIONS AND USAGE
TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
DOSAGE FORMS & STRENGTHS
Tablets: 150 mg and 200 mg
Manufactured By: Novartis Pharmaceuticals Corporation.
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “TABRECTA ™ (capmatinib) tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category Lung Cancer

TABRECTA ™ (capmatinib) tablets, for oral use.

Category Lung Cancer

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Description

Capmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Capmatinib is the first therapy approved by the US Food and Drug Administration (FDA) to treat non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).